KLKonstantin K. Laktionov

Konstantin K. Laktionov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Konstantin K. Laktionov has a total of 928 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cemiplimab plus chemotherapy versus chemotherapy in non-small-cell lung cancer with PD-L1 ≥1%: 5-year update of EMPOWER-Lung 3 Part 2 results

    by M. Gogishvili, T. Makharadze, T. Melkadze, D. Giorgadze, K. Penkov, K. Laktionov, E. Kalinka, G. Nemsadze, M. Nechaeva, I. Rozhkova, et al.

  • Open Access

    A clinical case of long-term intracranial monitoring during datopotamab deruxtecan therapy in a patient with EGFR-positive non-small cell lung cancer

    by M. N. Khagazheeva, E. V. Reutova, D. I. Yudin, V. V. Breder, K. K. Laktionov, М. Н. Хагажеева, Е. В. Реутова, Д. И. Юдин, В. В. Бредер, К. К. Лактионов

    Non-small cell lung cancer (NSCLC) is the second most common malignant neoplasm and the leading cause of tumor-related mortality worldwide. Despite a significant improvement in the treatment outcomes of patients with EGFR-positive NSCLC due to the introduction of third-generation tyrosine kinase inhibitors, the development of acquired resistance remains inevitable. Resistance to osimertinib in EGFR-mutated NSCLC is inevitable, and subsequent therapy options are limited, especially in CNS metastases. Antibody-drug conjugate open up new possibilities. A 49-year-old patient with EGFR L858R-positive NSCLC (stage IIIA), after progression on osimertinib (63 months) response and platinum-based chemoimmunotherapy. According to the MRI data, there are two metastatic foci in the brain. Datopotamab deruxtecan was started at a dose of 6 mg/kg every 3 weeks. After 7 cycles, a complete intracranial response was recorded, which persisted after 19 cycles. There was registered a progression of desease in 12 months of antibody-drug conjugate treatment. This case demonstrates the significant and prolonged intracranial activity of datopotamab deruxtecan in EGFR-mutated NSCLC resistant to osimertinib, as well as the phenomenon of dissociated response, which requires further study of resistance biomarkers.

  • Open Access

    Efficacy of alectinib in advanced ALK-positive non-small cell lung cancer: Results from the Russian multicenter KARL-005 study

    by D. T. Marinov, D. V. Perunov, L. N. Nefedova, I. S. Polyakov, A. F. Nasretdinov, A. A. Izmailov, A. V. Sultanbaev, M. I. Andrievskikh, R. A. Zukov, I. L. Obraz, et al.

    Introduction. Tyrosine kinase inhibitors, specifically alectinib, have significantly improved the prognosis for patients with advanced ALK-positive non-small cell lung cancer (ALK+ aNSCLC). National multicenter real-world data are essential to validate these outcomes within a broader clinical population. Aim. To evaluate the clinical efficacy of first-line alectinib in patients with ALK+ aNSCLC within routine clinical practice in the Russian Federation. Materials and methods. This multicenter retrospective study included patients who initiated first-line alectinib between 2020 and 2022. Primary endpoints included progression-free survival (PFS) and overall survival (OS) in the first-line setting. Secondary objectives assessed the prevalence of comorbidities and alectinib efficacy across clinical subgroups. Results. Data from 153 patients across 12 centers were analyzed. The median age was 56.7 years (range: 25.0–82.9), and 59.5% were female. At baseline, 21% of patients had an ECOG PS ≥ 2, and 20.3% presented with CNS metastases. Alectinib was administered as first-line therapy in 79 patients (51.6%), while 74 patients received it following prior chemotherapy. With a median follow-up of 47.8 months, the median PFS was 53.6 months (95% CI: 37.2 – NR) in the first-line cohort and 55.6 months (95% CI: 31.9 – NR) in the post-chemotherapy cohort. In the first-line group, median OS was not reached (5-year OS: 63.2%). For the post-chemotherapy group, median OS was 66.5 months (95% CI: 48.2 – NR; 5-year OS: 51.2%). Comorbidities were prevalent, notably cardiovascular disease (64.1%) and metabolic disorders (21.6%). Conclusion. Alectinib efficacy in Russian routine practice is comparable to the results of the landmark ALEX trial. The high prevalence of comorbidities highlights the need for a comprehensive, individualized approach to therapy selection in this population.

  • Open Access

    Pemigatinib in the real-world management of advanced intrahepatic FGFR2-positive cholangiocarcinoma

    by M. N. Khagazheeva, A. R. Zaretsky, A. N. Koshmanova, I. A. Dzhanyan, I. V. Savchenko, E. Yu. Antonova, K. K. Laktionov, V. V. Breder, М. М. Хагажеева, А. Р. Зарецкий, et al.

    Introduction. Cholangiocarcinoma (CC) is one of the most aggressive malignant tumors of the hepatobiliary tract with a poor prognosis, especially at the late stages. The targeted therapy with pemigatinib, a selective FGFR2 inhibitor, can be administered in a proportion (10–15%) of patients with intrahepatic cholangiocarcinoma (CC) harboring FGFR2 rearrangements/fusions. Aim. To evaluate the efficacy and safety of pemigatinib in second-line and subsequent lines of therapy for chemoresistant intrahepatic cholangiocarcinoma (CC) with FGFR2 rearrangements/fusions in real-world clinical practice. Mat erials and methods. The retrospective study included 68 patients with locally advanced/metastatic CC and confirmed FGFR2 alterations. The patients received pemigatinib in a standard regimen. Objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were assessed. Prognostic factors were analyzed using Cox regression and subgroup analysis. R esults. The majority of patients were female (70.6%). The patients received pemigatinib as second-line (39.7%), third-line (42.6%), and as subsequent (17.7%) lines of treatment. The ORR was 28%, with no complete responses recorded. The median PFS was 10.3 months (95% CI 8.2–16.7). The median OS was 16.1 months (95% CI 12.0–21.0), with a significantly higher OS in patients who achieved an objective response: 42.5 vs. 11.9 months (p < 0.0001). AEs were reported in 91.7% of patients, severe AEs (grade ≥3) in 19% of patients (most commonly hyperphosphatemia, arthralgia, and diarrhea). Dose reductions were required by 34.5% of patients; no toxicity events led to discontinuations. AEs did not impact OS (p = 0.45). C onclusion. Pemigatinib demonstrates high efficacy and acceptable safety in patients with FGFR2-altered CC in real-world clinical practice. Achieving an objective response is a robust favorable prognostic factor. An ECOG score of 2–3 and the use of pemigatinib as third-line and subsequent lines of treatment are independently associated with poor prognosis, confirming the need for early molecular genetic testing (NGS) and timely initiation of targeted therapy.

  • Open Access

    Remote results of treatment of patients with inoperable stage III non-small cell lung cancer (results of the observational study CARL-001)

    by K. K. Laktionov, V. V. Breder, A. K. Allakhverdiev, A. M. Kazakov, A. E. Gorokhov, P. V. Kononets, D. I. Yudin, D. L. Stroyakovskiy, Ya. S. Akhmadiyarova, V. V. Kozlov, et al.

    Introduction. This study examined the treatment outcomes of patients with inoperable stage III non-small cell lung cancer in real-world clinical practice. We determined the frequency and results of molecular genetic testing, and assessed long-term prognoses depending on the chemoradiotherapy regimen and the use of durvalumab maintenance therapy. Aim. To determine the impact of the type of chemoradiotherapy (concurrent or sequential) and the use of durvalumab maintenance therapy after completion of chemoradiotherapy on immediate and long-term treatment outcomes. Materials and methods. The results were obtained during the Lung Cancer Clinical Trial (CARL-001). The study included 166 patients with stage IIIA-IIIC NSCLC. The median age was 63 years. Stage distribution: stage IIIA – 65 patients (39.2%), stage IIIB – 77 (46.4%), and stage IIIC – 24 (14.5%). Patients were also divided by whether they received durvalumab maintenance therapy: 114 patients did not receive durvalumab and 52 did. Results. Molecular genetic analysis data for adenocarcinoma: EGFR status was determined in 39 patients – negative in all patients, not tested in 18 patients. ALK status was determined in 23 patients – negative in all patients, not tested in 34 patients. PD-L1 status (regardless of histotype) – tested in 56 patients, not tested in 110 patients. PD-L1 < 1% – 41 patients (73.3%), 1–49% – 14 patients (25%), 50% or higher –1 patient (1.7%). When comparing the efficacy of concurrent and sequential chemoradiation therapy in the group of patients without maintenance therapy with durvalumab, the following results were obtained: median relapse-free survival (RFS) was 10.0 months versus 12.0 months (sequential vs. concurrent, respectively) and median overall survival (OS) was 36.0 months versus not reached (sequential vs. concurrent, respectively). When comparing the efficacy of chemoimmunotherapy without durvalumab maintenance to chemoimmunotherapy with durvalumab maintenance, the following results were obtained: in the durvalumab group, the median RFS was 20 months, the median OS was not reached, and the objective response rate was 80%. In the group without durvalumab, the median RFS was 11.0 months, the median OS was not reached, and the objective response rate was 89.5%. Conclusions. Concurrent chemoradiotherapy showed a trend toward improved long-term treatment outcomes. Supplementing effective chemoradiotherapy with maintenance durvalumab improves long-term treatment outcomes, including an increase in median relapse-free survival and a trend toward improved overall survival.

  • Open Access

    Resolution on the results of the expert council on the topic “Diagnosis and treatment of advanced non-small cell lung cancer with BRAF mutation: from the search for molecular targets to therapeutic strategies in real-world clinical practice”

    by K. K. Laktionov, V. V. Breder, I. A. Demidova, V. V. Karaseva, F. V. Moiseenko, S. V. Orlov, E. V. Reutova, D. L. Stroyakovsky, К. К. Лактионов, В. В. Бредер, et al.

    On January 27, 2026, an Advisory Board was held to discuss issues of molecular genetic diagnosis of the BRAF V600E mutation in patients with advanced non-small cell lung cancer (NSCLC), as well as current treatment options for NSCLC patients with the BRAF V600E mutation. Next generation sequencing (NGS) is the most sensitive and specific method for molecular genetic testing. Its implementation in routine clinical practice will improve the detection rate of BRAF positive NSCLC patients. The accepted standard of care for patients with advanced NSCLC and the BRAF V600E mutation is targeted therapy with BRAF / MEK inhibitors. In the Russian Federation, the combination of dabrafenib and trametinib is approved for use. At the Advisory Board, results were presented from a study of a new targeted combination: encorafenib (a BRAF inhibitor) and binimetinib (a MEK inhibitor). In the Phase II PHAROS clinical trial, the encorafenib — binimetinib combination demonstrated a high rate and durability of antitumor response in adult patients with advanced NSCLC and the BRAF V600E mutation. The objective response rate in treatment naive and previously treated patient groups was 75 % and 49 %, respectively. The median progression free survival (PFS) in the subgroups was 30.4 months and 9.3 months, respectively. At the time of publication, the indication “advanced NSCLC with the BRAF V600E mutation” for the targeted drug combination of encorafenib and binimetinib has not been registered in the Russian Federation.

  • Real-world outcomes of atezolizumab in pretreated patients with metastatic non-small cell lung cancer

    by D.I. Yudin, K.K. Laktionov, V.V. Breder

    Immunotherapy is a highly effective second-line option for advanced NSCLC. Long-term outcomes of two randomized phase 2 POPLAR and phase 3 OAK studies revealed a survival benefit with atezolizumab in patients with previously treated NSCLC regardless of the level of PD-L1 expression or histology. Objective. To evaluate the real-world effectiveness and safety of atezolizumab in previously treated patients with metastatic NSCLC. Material and methods. This single-site retrospective study included previously treated patients with metastatic NSCLC who received atezolizumab between 2019 and 2023 in the N. N. Blokhin National Research Medical Center of Oncology. Primary endpoints were real-world progression-free survival (PFS) and overall survival (OS) rates. Results. 62 patients were included in the study. The median follow-up time was 53.55 months. The median PFS and OS for the patients receiving atezolizumab were 6.9 months (95% CI 1.69—12.1) and 16.4 months (95% CI 10.99—21.8), respectively. The 5-year PFS and OS rates were 5.3% and 21.2%, respectively. Multivariate analysis identified clinical trials ineligibility (ECOG performance status 2—3, comorbidities, acute infection, corticosteroids) and CNS metastasis as significant independent negative predictors of overall survival (HR=2.11, p=0.021 and HR=2.41, p=0.016, respectively). 4 (6.4%) patients had immune-related adverse events (irAE) grade 3—4. The median time to irAE any grade from the start of atezolizumab was 9.5 (min—max: 1—52) months. Conclusion. The patients without CNS metastasis and eligible to clinical trials had better real-world five-year outcomes of atezolizumab in second+ line treatment.

  • Open Access

    Long-term real-world outcomes in patients with metastatic non-small cell lung cancer and immune-mediated adverse events

    by D. I. Yudin, Юдин Д. И., K. K. Laktionov, Лактионов К. К., I. A. Djanyan, Джанян И. А.

    Background. The negative side of immunotherapy with immune checkpoint inhibitors for patients with metastatic non-small cell lung cancer (NSCLC) is the development of immune-mediated adverse events (imAE). Aim. To determine the association between imAE and overall survival (OS), progression-free survival (PFS) in patients with metastatic NSCLC receiving immunotherapy. Materials and methods. The study included data on treatment of patients with metastatic NSCLC who received immunotherapy at the N. N. Blokhin National Medical Research Center of Oncology between 2015 and 2023. The patients were divided into two groups: those who developed any grade imAE and those who did not. The primary endpoints of the study were PFS and OS. Landmark analysis was performed to avoid immortal time bias. Results. The study included 461 patients. Any grade imAE occurred in 138 patients, while 323 patients did not experience imAE. The median follow-up time was 60.7 months. For the patients with and without imAE in a 16-month landmark analysis, median OS was 70.0 months (95 % confidence interval (CI) 39.93–100.06) and 45.4 months (95 % CI 38.78–52.01) (p = 0.048), respectively. And in a 6.5-month landmark analysis, median PFS was 16.7 months (95 % CI 1.25–32.14) and 20.6 months (95 % CI 14.98–26.21) (p = 0.942) for patients with and without imAE, respectively. Conclusion. Immune-mediated adverse events during immunotherapy in patients with metastatic NSCLC are associated with better overall survival when a landmark analysis was applied.

  • Open Access

    Supplementary Data from Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non–Small Cell Lung Cancer

    by Jhanelle E. Gray, Konstantin Laktionov, Sang-We Kim, Terufumi Kato, Jialei Wang, Zhigang Han, Paul Mitchell, Shoichi Kuyama, Jerry Tan Chun Bing, Juan Cundom, et al.

    Supplementary Table S1. Representativeness of study participants Supplementary Table S2. Averagea change from baseline in prespecified key EORTC QLQ-C30 and QLQ-LC13 scale scores over all timepoints (MMRM). Supplementary Figure S1. Patient-reported outcome assessment schedules in FLAURA2. Supplementary Figure S2. Patient-reported outcome questionnaire compliance rates. Supplementary Figure S3. Proportion of patients with different A, frequency and B, severity scores for the additional prespecified PRO-CTCAE symptoms at different timepoints. Weeks 13 (3.0 months), 37 (8.5 months), and 97 (22.3 months) of the PRO-CTCAE assessments represent the closest available timepoints to the end of the induction, median pemetrexed maintenance and median osimertinib treatment, respectively, for the osimertinib plus chemotherapy arm. Conditional branching logic was employed for PRO-CTCAE symptom terms that have two or more attributes, thereby reducing the sample size from frequency to severity for symptoms. PRO-CTCAE, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events

  • Open Access

    Data from Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non–Small Cell Lung Cancer

    by Jhanelle E. Gray, Konstantin Laktionov, Sang-We Kim, Terufumi Kato, Jialei Wang, Zhigang Han, Paul Mitchell, Shoichi Kuyama, Jerry Tan Chun Bing, Juan Cundom, et al.

    Purpose:In FLAURA2, first-line osimertinib plus platinum–pemetrexed induction, with osimertinib plus pemetrexed maintenance, improved progression-free survival versus osimertinib alone in epidermal growth factor receptor (EGFR)-mutated, advanced non–small cell lung cancer (NSCLC; hazard ratio, 0.62; P < 0.001). Combining osimertinib with chemotherapy increased induction grade ≥3 adverse event rates, which reduced during maintenance. We report FLAURA2 patient-reported outcomes (PRO).Patients and Methods:Health-related quality of life (HRQoL) was measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) Core 30 (baseline, week 4, week 7, week 10, then every 6 weeks until progression) and QLQ Lung Cancer 13 (baseline, weekly until week 10, then every 3 weeks until progression). Score changes (baseline to progression/19 months) were analyzed by mixed models for repeated measures. Within-patient ≥10-point changes from baseline were considered clinically meaningful. Tolerability was assessed by PRO-Common Terminology Criteria for Adverse Events (CTCAE).Results:Patients had intermediate-to-high baseline functioning and global health status (GHS)/QoL (mean scores ≥63), with mild symptomatology (≤35). Most key scales showed nonclinically meaningful improvements; average least-squares mean (LSM) changes [95% confidence interval (CI)] for GHS/QoL and physical function, respectively, were 3.32 (1.67–4.98) and 2.37 (0.70–4.04) with combination therapy and 7.38 (5.70–9.07) and 6.74 (5.04–8.43) with monotherapy. Improvements in cough were clinically meaningful with combination therapy and monotherapy from week 5 (except monotherapy at week 73); average LSM changes (95% CI) were −13.23 (−14.85 to −11.62) and −11.19 (−12.83 to −9.55), respectively. Nonclinically meaningful deteriorations in fatigue and appetite loss were seen with the combination during induction. Both treatments were similarly well tolerated (PRO-CTCAE).Conclusions:In FLAURA2, osimertinib monotherapy and combination with platinum–pemetrexed as first-line treatment for EGFR-mutated advanced NSCLC had nonclinically meaningful impacts on HRQoL in mildly symptomatic patients.